Oncologic outcomes, prognostic factor analysis and therapeutic algorithm evaluation of head and neck mucosal melanomas in France.


Journal

European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373

Informations de publication

Date de publication:
12 2019
Historique:
received: 11 02 2019
revised: 03 05 2019
accepted: 10 09 2019
pubmed: 2 11 2019
medline: 17 6 2020
entrez: 1 11 2019
Statut: ppublish

Résumé

Head and neck mucosal melanoma (HNMM) is aggressive and rare, with a poor prognosis because of its high metastatic potential. The two main subtypes are sinonasal (sinonasal mucosal melanoma [SNMM]) and oral cavity (oral cavity mucosal melanoma [OCMM]). Consensual therapeutic guidelines considering the primary tumour site and tumour-node-metastasis (TNM) stage are not well established. Patients with HNMM from the prospective national French Rare Head and Neck Cancer Expert Network database between 2000 and 2017 were included. Clinical characteristics, treatment modalities, outcomes and prognostic factors were analysed. In total, 314 patients were included. The 5-year overall survival (OS) and progression-free survival (PFS) rates were 49.4% and 24.7%, respectively, in the surgery group; no long-term survivors were observed when surgery was not feasible. Moreover, even after surgery, a high recurrence rate was reported with a median PFS of 22 months. In multivariate analysis, Union for International Cancer Control (UICC) stage and tumour site correlated with PFS and OS. Postoperative radiotherapy (PORT) improved the PFS but not OS in patients with small (T3) SNMM and OCMM tumours. Nodal involvement was more frequent in patients with OCMM (p < 10 Even early HNMM was associated with poor oncologic outcomes due to distant metastases despite surgical resection with clear margins. Lymph node metastases had no impact on the prognosis, suggesting treatment de-escalation in cervical node management. PORT might be useful for local control.

Sections du résumé

BACKGROUND
Head and neck mucosal melanoma (HNMM) is aggressive and rare, with a poor prognosis because of its high metastatic potential. The two main subtypes are sinonasal (sinonasal mucosal melanoma [SNMM]) and oral cavity (oral cavity mucosal melanoma [OCMM]). Consensual therapeutic guidelines considering the primary tumour site and tumour-node-metastasis (TNM) stage are not well established.
MATERIAL & METHODS
Patients with HNMM from the prospective national French Rare Head and Neck Cancer Expert Network database between 2000 and 2017 were included. Clinical characteristics, treatment modalities, outcomes and prognostic factors were analysed.
RESULTS
In total, 314 patients were included. The 5-year overall survival (OS) and progression-free survival (PFS) rates were 49.4% and 24.7%, respectively, in the surgery group; no long-term survivors were observed when surgery was not feasible. Moreover, even after surgery, a high recurrence rate was reported with a median PFS of 22 months. In multivariate analysis, Union for International Cancer Control (UICC) stage and tumour site correlated with PFS and OS. Postoperative radiotherapy (PORT) improved the PFS but not OS in patients with small (T3) SNMM and OCMM tumours. Nodal involvement was more frequent in patients with OCMM (p < 10
CONCLUSION
Even early HNMM was associated with poor oncologic outcomes due to distant metastases despite surgical resection with clear margins. Lymph node metastases had no impact on the prognosis, suggesting treatment de-escalation in cervical node management. PORT might be useful for local control.

Identifiants

pubmed: 31670075
pii: S0959-8049(19)30729-4
doi: 10.1016/j.ejca.2019.09.007
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-10

Investigateurs

S Albert (S)
G Andry (G)
E Babin (E)
C Bach (C)
J-M Badet (JM)
C Badoual (C)
A C Baglin (AC)
A Banal (A)
B Barry (B)
E Baudin (E)
B Baujat (B)
R J Bensadoun (RJ)
C Bertolus (C)
J-P Bessède (JP)
D Blanchard (D)
C Borel (C)
A Bozorg-Grayeli (A)
R Breheret (R)
P Breton (P)
L Brugel (L)
G Calais (G)
O Casiraghi (O)
E Cassagnau (E)
L Castillo (L)
P Ceruse (P)
F Chabolle (F)
D Chevalier (D)
J C Chobaut (JC)
O Choussy (O)
A Cosmidis (A)
A Coste (A)
V Costes (V)
L Crampette (L)
V Darrouzet (V)
P Demez (P)
P Dessi (P)
B Devauchelle (B)
L Digue (L)
G Dolivet (G)
F Dubrulle (F)
S Duflo (S)
X Dufour (X)
C Even (C)
S Faivre (S)
N Fakhry (N)
C Ferron (C)
F Floret (F)
L de Gabory (L)
R Garrel (R)
L Geoffrois (L)
L Gilain (L)
A Giovanni (A)
A Girod (A)
B Guerrier (B)
S Hans (S)
P Herman (P)
P Hofman (P)
M Housset (M)
R Jankowski (R)
F Jegoux (F)
M Juliéron (M)
M-C Kaminsky (MC)
F Kolb (F)
J Lacau St Guily (J)
L Laccoureye (L)
B Lallemant (B)
P Lang (P)
E Lartigau (E)
J-P Lavieille (JP)
M Lefevre (M)
X Leroy (X)
O Malard (O)
F Massip (F)
O Mauvais (O)
J-C Merol (JC)
J Michel (J)
T Mom (T)
S Morinière (S)
E de Monès (E)
G Moulin (G)
A Moya-Plana (A)
G Noel (G)
G Poissonnet (G)
J-M Prades (JM)
D de Raucourt (D)
E Reyt (E)
C Righini (C)
Y Marie Robin (Y)
F Rolland (F)
B Ruhin (B)
N Sarroul (N)
P Schultz (P)
E Serrano (E)
O Sterkers (O)
V Strunski (V)
A Sudaka (A)
M Tassart (M)
S Testelin (S)
J Thariat (J)
A Timochenko (A)
B Toussaint (B)
E Uro Coste (E)
G Valette (G)
T Van den Abbeele (T)
A Varoquaux (A)
F Veillon (F)
S Vergez (S)
B Vérillaud (B)
M Wassef (M)

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

A Moya-Plana (A)

Head and Neck Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France. Electronic address: antoine.moya-plana@gustaveroussy.fr.

A Aupérin (A)

Biostatistics Department, Gustave Roussy Cancer Campus, Villejuif, France.

R Obongo (R)

Head and Neck Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France.

A Baglin (A)

Department of Pathology, Lariboisière Hospital, Paris, France.

F R Ferrand (FR)

Head and Neck Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France; Medical Oncology Department, HIA Begin, Saint Mandé, France.

B Baujat (B)

Head and Neck Surgery Department, Tenon Hospital, Paris, France.

N Saroul (N)

Head and Neck Surgery Department, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.

O Casiraghi (O)

Department of Pathology, Gustave Roussy Cancer Campus, Villejuif, France.

S Vergez (S)

Head and Neck Surgery Department, Toulouse University Hospital Center, Toulouse, France.

P Herman (P)

Head and Neck Surgery Department, Lariboisière Hospital, Paris, France.

F Janot (F)

Head and Neck Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France.

J Thariat (J)

Radiation Oncology Department, Baclesse Cancer Center, Caen, France.

B Vérillaud (B)

Head and Neck Surgery Department, Lariboisière Hospital, Paris, France.

L de Gabory (L)

Head and Neck Surgery Department, Pellegrin Hospital, Centre Michelet, Bordeaux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH